FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension

May 18, 2026 06:01 AM EDT PharmaFDA+ As­traZeneca's blood pres­sure pill ap­proved, but com­pe­ti­tion could be around the cor­ner Elizabeth Cairns Senior biopharma journalist One of the key prod­ucts un­der­pin­ning As­traZeneca’s goal of hit­ting $80 bil­lion in rev­enue by 2030 has been ap­proved by the FDA … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER